Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9418732 | 0.78 | GRIK1 (0.53) | GRIK1TSHRTET2GRIK2KDM4E | |
| SCHEMBL7174695 | 0.78 | GRIK1 (0.53) | GRIK1TSHRTET2GRIK2KDM4E | |
| SCHEMBL14723746 | 0.78 | GRIK1 (0.53) | GRIK1TSHRTET2GRIK2KDM4E | |
| SCHEMBL7866400 | 0.76 | TSHR (0.35) | GRIK1TSHRKDM4E | |
| SCHEMBL7866399 | 0.76 | TSHR (0.35) | GRIK1TSHRKDM4E | |
| SCHEMBL14280076 | 0.76 | GRIK1 (0.52) | GRIK1TSHRTET2GRIK2KDM4E | |
| SCHEMBL395188 | 0.74 | GRIK1 (0.50) | GRIK1TSHRTET2GRIK2 | |
| SCHEMBL346378 | 0.74 | — | — | |
| SCHEMBL7067796 | 0.74 | — | — | |
| SCHEMBL7067793 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452254-A2 | TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | The Katholieke Universiteit Leuven (BE) | 2024-10-30 | — | — | EP | disclosed |
| US-20230279016-A1 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | CISTIM LEUVEN VZW (BE) | 2023-09-07 | — | — | US | disclosed |
| WO-2023122783-A2 | TETRAHYDROPYRAZOLOPYRIMIDINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD | THE KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279016-A1 | Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD1 | GRIK1 4061/4885TSHR 2776/4885TRPA1 4547/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | GRIK1 4546/4885TSHR 3882/4885TRPA1 4823/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | GRIK1 4546/4885TSHR 3882/4885TRPA1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.